INTRODUCTION AND OBJECTIVES: Transperineal injection of a degradable hydrogel, (SpaceOAR,Augmenix, Bedford, MA) is FDA approved for expanding the space between the prostate and rectum during radiation therapy (RT) to reduce rectal dose. We previously described the use of this agent in treating patients undergoing salvage cryoablation (SC) for recurrent prostate cancer (CaP). We now report patient outcomes after one year of use of this novel modality at our institution.
METHODS: We analyzed results of patients who underwent SC of the prostate with concomitant injection of SpaceOAR from July 2017 to July 2018. Postoperative outcomes at 2 weeks 3, 6, 9 and 12 months are reported using the Clavien-Dindo Classification along with PSA values for patients with available data.
RESULTS: 16 patients underwent cryoablation of the prostate with the injection of SpaceOAR; 15 SC and 1 primary cryoablation. Mean age was 69 years; initial clinical stratification was low (5/16), intermediate CaP (2/16), high risk (1/16) and 8 patients with unknown pathology at time of cryotherapy. Previous treatment for those undergoing salvage cryoablation consisted of radiation alone (7/16), radiation plus androgen deprivation therapy (4/16), external beam, brachytherapy and androgen deprivation therapy (2/16), radiation followed by salvage cryotherapy (1/16), proton beam therapy (1/16). A mean prostate volume of 20.3g was recorded. At initial post-operative follow up, a third of patients reported a grade 1 complication including scrotal swelling, perineal pain or dysuria (5/15) with one patient reporting a grade 2 complication (inpatient admission for UTI at an outside facility). At 3 months postop, two patients continued to have grade 1 complications (perineal pain) and one patient that had previously undergone SC presented with a grade 3 complication (rectoprostatic fistula). No further complications were noted. No grade 4-5 complications have been noted. The patient with the rectorprostatic fistula required further surgical intervention for repair. PSA nadired to undetectable as defined as PSA <0.1ng/dl in 40% of patients with at least 3 month follow up with PSA data (4/10).
CONCLUSIONS: Use of SpaceOAR with SC is associated with minor complications with only one reported grade 3 complication in our series. PSA was undetectable in large portion of patients after SC likely due to ability to aggressively freeze the prostate gland safely with use of this hydrogel spacer. Further studies evaluating the long term oncologic and functional outcomes of this new technique are needed.
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PD23-11 DIAGNOSTIC ACCURACY OF CONTRAST-ENHANCED VOIDING UROSONOGRAM USING SECOND GENERATION CONTRAST WITH HARMONIC IMAGING (CEVUS-HI) IN THE DIAGNOSIS OF VESICOURETERAL REFLUX (VUR) IN CHILDREN: A META-ANALYSIS
Jonathan Mendoza*, Rogerson Tiangco, Michael Chua, Jun Dy, Odina Gomez, Quezon city, Philippines INTRODUCTION AND OBJECTIVES: Vesicoureteral Reflux (VUR) is a common condition affecting 34.8 to 37.4% of all pediatric populations worldwide. Prompt diagnosis and adequate management is required to avoid serious long-term sequelae like renal failure. We aim to assess the diagnostic accuracy and safety of contrast enhanced urosonography using second generation contrast with harmonic imaging (CEVUS-HI) based on standard fluoroscopic voiding cystourethrogram (VCUG) in detecting VUR among children.
METHODS: Literature search was performed on several medical databases on March 8, 2018. Comparative studies were independently screened and assessed by three reviewers. Study quality was appraised using QUADAS-2 tool. Diagnostic accuracy of sensitivity (Sn), Specificity (Sp), positive likelihood ratio (pLR), negative likelihood ratio (nLR) and diagnostic odds ratio (dOR) were determined with VCUG as the reference standard. Adverse effects were summarized. The inter study variability, and heterogeneity and its possible source were determined and investigated via bivariate model metaregression and configuration of summarizing receiver operator characteristics (SROC). Assessment of the likelihood of publication bias was also done.
RESULTS: A total of 12 studies with low to moderate risk of bias, including 1,917 ureteral units from 953 patients were assessed. The studies reported no associated serious adverse events. CONCLUSIONS: Based on VCUG as reference standard, the pooled diagnostic accuracy parameters have illustrated that CEVUS-HI is highly accurate in detecting VUR amongst children. Its excellent safety profile and absence of radiation exposure allows for its use as an alternative for screening and follow-up of VUR especially in highly specialized centers.
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PD23-12 INVESTIGATION OF A RADIOPAQUE TAPE MARKER TO PREVENT WRONG SIDED SURGERY IN FLUOROSCOPICALLY GUIDED ENDOSCOPIC KIDNEY PROCEDURES
Colby Dixon*, Resha Tejpaul, Michael Borofsky, Minneapolis, MN INTRODUCTION AND OBJECTIVES: Though uncommon, the medicolegal ramifications of wrong sided surgery are catastrophic. While skin marking is a proven technique to confirm laterality in open surgical procedures, it is less useful in endoscopic procedures as markings are covered by drapes and not visible on fluoroscopic imaging. Recently a novel radiopaque tape marker ("X Site", Target Tape Inc; Surrey, British Columbia) was introduced to assist in confirming laterality for patients undergoing endourologic surgery. We sought to assess this in clinical practice.
METHODS: 40 patients undergoing upper tract endourologic surgery had an X Site sticker applied preoperatively to their torso 4 fingerbreadths lateral to the umbilicus. Visualization of the sticker was then confirmed on intraoperative fluoroscopic imaging. Patients and surgeons were surveyed 1-2 days following the procedure regarding their satisfaction with the sticker as well as intraoperative or postoperative issues with its use.
RESULTS: The X Site sticker was readily apparent on fluoroscopy when placed 4 fingerbreadths lateral to the umbilicus in all but one case despite a wide range in patient body mass index (22.7-43.8, mean 29.9 ). There were no cases of the sticker being dislodged or obscuring views of the kidney or ureter. Among respondents to the post procedure survey, there were no reports of local reaction from sticker application. The majority of patients (11/14, 79%) reported that the sticker improved their concerns about wrong sided surgery.
CONCLUSIONS: We found the X Site marker to be reliable and readily identifiable in 95% of cases when applied in the described fashion. Application of the X Site sticker has the potential to improve patient safety and prevent wrong sided endourologic surgery by allowing real time confirmation of laterality on fluoroscopic imaging. Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e397
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